The validity of uridine supplementation in the context of nervous system aging Review article
Article Sidebar
Published:
Dec 31, 2024
Keywords:
uridine, supplementation, neurological disorders, neuroprotection, nervous system
Main Article Content
Abstract
This article discusses the rationale for uridine supplementation in the context of neurological disorders, focusing on its effects on nervous system function. Uridine, a key pyrimidine nucleoside, plays a crucial role in phospholipid synthesis, neuronal membrane repair, neurotransmitter production, and neuroprotective processes. Studies indicate that uridine supplementation, particularly when combined with B vitamins, may support synapse regeneration and improve neural conductivity.
The article provides a detailed analysis of clinical evidence supporting uridine supplementation, particularly in counteracting processes leading to nervous system aging. Research on ischemic brain injury has demonstrated that uridine administration can enhance memory and reduce atrophy. In peripheral neuropathies, its beneficial effects have been documented in reducing neuropathic pain and promoting nerve regeneration. In conclusion, uridine supplementation may represent a promising therapeutic strategy for neuroprotection, cognitive function support, and nervous system regeneration.
Article Details
How to Cite
Żur-Wyrozumska, K. (2024). The validity of uridine supplementation in the context of nervous system aging. Medycyna Faktow (J EBM), 17(4(65), 538-542. https://doi.org/10.24292/01.MF.0424.16
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. DeCarli C, Massaro J, Harvey D et al. Measures of brain morphology and infarction in the framingham heart study: establishing what is normal. Neurobiol Aging. 2005; 26(4): 491-510. http://doi.org/10.1016/j.neurobiolaging.2004.05.004.
2. Blinkouskaya Y, Caçoilo A, Gollamudi T et al. Brain aging mechanisms with mechanical manifestations. Mech Ageing Dev. 2021; 200: 111575.
3. Petersen RC, Roberts RO, Knopman DS et al. Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. Neurology. 2010; 75(10): 889-97. http://doi.org/10.1212/WNL.0b013e3181f11d85.
4. Erkinjuntti T, Gauthier S. The concept of vascular cognitive impairment. Front Neurol Neurosci. 2009; 24: 79-85. http://doi.org/10.1159/000197886.
5. Agüero-Torres H, Fratiglioni L, Guo Z et al. Prognostic factors in very old demented adults: a seven-year follow-up from a population-based survey in Stockholm. J Am Geriatr Soc. 1998; 46(4): 444-52. http://doi.org/10.1111/j.1532-5415.1998.tb02464.x.
6. Samson WN, van Duijn CM, Hop WC et al. Clinical features and mortality in patients with early-onset Alzheimer’s disease. Eur Neurol. 1996; 36(2): 103-6. http://doi.org/10.1159/000117218.
7. Piechal A, Członkowska A. Otępienie naczyniopochodne. In: Stępień A. (ed.). Neurologia. Tom 2. Medical Tribune Polska, Warszawa 2020.
8. Wurtman RJ, Cansev M, Ulus IH. Synapse formation is enhanced by oral administration of uridine and DHA, the circulating precursors of brain phosphatides. J Nutr Health Aging. 2009; 13(3): 189-97.
9. Engelborghs S, Gilles C, Ivanoiu A et al. Rationale and clinical data supporting nutritional intervention in Alzheimer’s disease. Acta Clin Belg. 2014; 69(1): 17-24. http://doi.org/10.1179/0001551213Z.0000000006.
10. Goren B, Cakir A, Sevinc C et al. Uridine treatment protects against neonatal brain damage and long-term cognitive deficits caused by hyperoxia. Brain Res. 2017; 1676: 57-68. http://doi.org/10.1016/j.brainres.2017.09.010.
11. Al N, Çakir A, Koç C et al. Antioxidative effects of uridine in a neonatal rat model of hyperoxic brain injury. Turk J Med Sci. 2020; 50(8): 2059-66. http://doi.org/10.3906/sag-2002-14.
12. Goren B, Cakir A, Ocalan B et al. Long-term cognitive effects of uridine treatment in a neonatal rat model of hypoxic-ischemic encephalopathy. Brain Res. 2017; 1659: 81-7. http://doi.org/10.1016/ j.brainres.2017.01.026.
13. Scheltens P, Kamphuis PJ, Verhey FR et al. Efficacy of a medical food in mild Alzheimer’s disease: A randomized, controlled trial. Alzheimers Dement. 2010; 6(1): 1-10.e1. http://doi.org/10.1016/ j.jalz.2009.10.003.
14. Scheltens P, Twisk JW, Blesa R et al. Efficacy of Souvenaid in mild Alzheimer’s disease: results from a randomized, controlled trial. J Alzheimers Dis. 2012; 31(1): 225-36. http://doi.org/10.3233/JAD-2012-121189.
15. van Wijk N, Broersen LM, de Wilde MC et al. Targeting synaptic dysfunction in Alzheimer’s disease by administering a specific nutrient combination. J Alzheimers Dis. 2014; 38(3): 459-79. http://doi.org/10.3233/JAD-130998.
16. Chimakurthy AK, Lingam S, Pasya SKR et al. A Systematic Review of Dietary Supplements in Alzheimer’s Disease. Cureus. 2023; 15(1): e33982. http://doi.org/10.7759/cureus.33982.
17. Cummings J, Scheltens P, McKeith I et al. Effect Size Analyses of Souvenaid in Patients with Alzheimer’s Disease. J Alzheimers Dis. 2017; 55(3): 1131-9. http://doi.org/10.3233/JAD-160745.
18. Cummings J, Passmore P, McGuinness B et al. Souvenaid in the management of mild cognitive impairment: an expert consensus opinion. Alzheimers Res Ther. 2019; 11(1): 73. http://doi.org/10.1186/ s13195-019-0528-6.
19. Rasmussen J. The LipiDiDiet trial: what does it add to the current evidence for Fortasyn Connect in early Alzheimer’s disease? Clin Interv Aging. 2019; 14: 1481-92. http://doi.org/10.2147/CIA.S211739.
20. Goldberg H, Mibielli MA, Nunes CP et al. A double-blind, randomized, comparative study of the use of a combination of uridine triphosphate trisodium, cytidine monophosphate disodium, and hydroxocobalamin, versus isolated treatment with hydroxocobalamin, in patients presenting with compressive neuralgias. J Pain Res. 2017; 10: 397-404. http://doi.org/10.2147/JPR.S123045.
21. Negrão L, Almeida P, Alcino S et al. Effect of the combination of uridine nucleotides, folic acid and vitamin B12 on the clinical expression of peripheral neuropathies. Pain Manag. 2014; 4(3): 191-6. http://doi.org/10.2217/pmt.14.10.
22. Negrão L, Nunes P; Portuguese Group for the Study of Peripheral Neuropathy. Uridine monophosphate, folic acid and vitamin B12 in patients with symptomatic peripheral entrapment neuropathies. Pain Manag. 2016; 6(1): 25-9. http://doi.org/10.2217/pmt.15.60.
23. Monfort J, Carrión-Barberà I, Tío L et al. Evaluation of the Efficacy of the Addition of a Combination of Pyrimidine Nucleotides and Vitamin B1 and B12 to Standard Treatment in the Management of Painful Radiculopathy and in the Quality of Life of Patients. Nutrients. 2024; 16(23): 4187. http://doi.org/10.3390/nu16234187.
24. Mibielli MAN, Nunes CP, Goldberg H et al. Nucleotides Cytidine and Uridine Associated with Vitamin B12 vs B-Complex Vitamins in the Treatment of Low Back Pain: The NUBES Study. J Pain Res. 2020; 13: 2531-41. http://doi.org/10.2147/JPR.S277024.
2. Blinkouskaya Y, Caçoilo A, Gollamudi T et al. Brain aging mechanisms with mechanical manifestations. Mech Ageing Dev. 2021; 200: 111575.
3. Petersen RC, Roberts RO, Knopman DS et al. Prevalence of mild cognitive impairment is higher in men. The Mayo Clinic Study of Aging. Neurology. 2010; 75(10): 889-97. http://doi.org/10.1212/WNL.0b013e3181f11d85.
4. Erkinjuntti T, Gauthier S. The concept of vascular cognitive impairment. Front Neurol Neurosci. 2009; 24: 79-85. http://doi.org/10.1159/000197886.
5. Agüero-Torres H, Fratiglioni L, Guo Z et al. Prognostic factors in very old demented adults: a seven-year follow-up from a population-based survey in Stockholm. J Am Geriatr Soc. 1998; 46(4): 444-52. http://doi.org/10.1111/j.1532-5415.1998.tb02464.x.
6. Samson WN, van Duijn CM, Hop WC et al. Clinical features and mortality in patients with early-onset Alzheimer’s disease. Eur Neurol. 1996; 36(2): 103-6. http://doi.org/10.1159/000117218.
7. Piechal A, Członkowska A. Otępienie naczyniopochodne. In: Stępień A. (ed.). Neurologia. Tom 2. Medical Tribune Polska, Warszawa 2020.
8. Wurtman RJ, Cansev M, Ulus IH. Synapse formation is enhanced by oral administration of uridine and DHA, the circulating precursors of brain phosphatides. J Nutr Health Aging. 2009; 13(3): 189-97.
9. Engelborghs S, Gilles C, Ivanoiu A et al. Rationale and clinical data supporting nutritional intervention in Alzheimer’s disease. Acta Clin Belg. 2014; 69(1): 17-24. http://doi.org/10.1179/0001551213Z.0000000006.
10. Goren B, Cakir A, Sevinc C et al. Uridine treatment protects against neonatal brain damage and long-term cognitive deficits caused by hyperoxia. Brain Res. 2017; 1676: 57-68. http://doi.org/10.1016/j.brainres.2017.09.010.
11. Al N, Çakir A, Koç C et al. Antioxidative effects of uridine in a neonatal rat model of hyperoxic brain injury. Turk J Med Sci. 2020; 50(8): 2059-66. http://doi.org/10.3906/sag-2002-14.
12. Goren B, Cakir A, Ocalan B et al. Long-term cognitive effects of uridine treatment in a neonatal rat model of hypoxic-ischemic encephalopathy. Brain Res. 2017; 1659: 81-7. http://doi.org/10.1016/ j.brainres.2017.01.026.
13. Scheltens P, Kamphuis PJ, Verhey FR et al. Efficacy of a medical food in mild Alzheimer’s disease: A randomized, controlled trial. Alzheimers Dement. 2010; 6(1): 1-10.e1. http://doi.org/10.1016/ j.jalz.2009.10.003.
14. Scheltens P, Twisk JW, Blesa R et al. Efficacy of Souvenaid in mild Alzheimer’s disease: results from a randomized, controlled trial. J Alzheimers Dis. 2012; 31(1): 225-36. http://doi.org/10.3233/JAD-2012-121189.
15. van Wijk N, Broersen LM, de Wilde MC et al. Targeting synaptic dysfunction in Alzheimer’s disease by administering a specific nutrient combination. J Alzheimers Dis. 2014; 38(3): 459-79. http://doi.org/10.3233/JAD-130998.
16. Chimakurthy AK, Lingam S, Pasya SKR et al. A Systematic Review of Dietary Supplements in Alzheimer’s Disease. Cureus. 2023; 15(1): e33982. http://doi.org/10.7759/cureus.33982.
17. Cummings J, Scheltens P, McKeith I et al. Effect Size Analyses of Souvenaid in Patients with Alzheimer’s Disease. J Alzheimers Dis. 2017; 55(3): 1131-9. http://doi.org/10.3233/JAD-160745.
18. Cummings J, Passmore P, McGuinness B et al. Souvenaid in the management of mild cognitive impairment: an expert consensus opinion. Alzheimers Res Ther. 2019; 11(1): 73. http://doi.org/10.1186/ s13195-019-0528-6.
19. Rasmussen J. The LipiDiDiet trial: what does it add to the current evidence for Fortasyn Connect in early Alzheimer’s disease? Clin Interv Aging. 2019; 14: 1481-92. http://doi.org/10.2147/CIA.S211739.
20. Goldberg H, Mibielli MA, Nunes CP et al. A double-blind, randomized, comparative study of the use of a combination of uridine triphosphate trisodium, cytidine monophosphate disodium, and hydroxocobalamin, versus isolated treatment with hydroxocobalamin, in patients presenting with compressive neuralgias. J Pain Res. 2017; 10: 397-404. http://doi.org/10.2147/JPR.S123045.
21. Negrão L, Almeida P, Alcino S et al. Effect of the combination of uridine nucleotides, folic acid and vitamin B12 on the clinical expression of peripheral neuropathies. Pain Manag. 2014; 4(3): 191-6. http://doi.org/10.2217/pmt.14.10.
22. Negrão L, Nunes P; Portuguese Group for the Study of Peripheral Neuropathy. Uridine monophosphate, folic acid and vitamin B12 in patients with symptomatic peripheral entrapment neuropathies. Pain Manag. 2016; 6(1): 25-9. http://doi.org/10.2217/pmt.15.60.
23. Monfort J, Carrión-Barberà I, Tío L et al. Evaluation of the Efficacy of the Addition of a Combination of Pyrimidine Nucleotides and Vitamin B1 and B12 to Standard Treatment in the Management of Painful Radiculopathy and in the Quality of Life of Patients. Nutrients. 2024; 16(23): 4187. http://doi.org/10.3390/nu16234187.
24. Mibielli MAN, Nunes CP, Goldberg H et al. Nucleotides Cytidine and Uridine Associated with Vitamin B12 vs B-Complex Vitamins in the Treatment of Low Back Pain: The NUBES Study. J Pain Res. 2020; 13: 2531-41. http://doi.org/10.2147/JPR.S277024.